Slide 1: Q3 2022 Results Call
| Ce KemPharm Q3 2022 Results Call November 9, 2022 “a Trademarks herein are held by their respective owners.
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, includin
Slide 3: Q3 2022 Results Call Agenda
Q3 2022 Results Call Agenda 1) Introduction 2) Product Development Updates 3) Financial Update 4) Question and Answer Travis Mickle, Ph.D. President and Chief Executive Officer Travis Mickle R. LaDuane Clifton, CPA Chief Financial Officer, Secretary & Treasurer
Slide 4: KemPharm: Innovative biotech with proven regulatory track record
KEMPH Innovative biotech company with a proven regulatory track record targeting rare CNS, neurodegenerative and lysosomal storage diseases
Slide 5: KemPharm: Q3 2022 and Recent Highlights
KemPharm: Q3 2022 and Recent Highlights v Completion of the 4-year safety trial v Phase 1 cardiovascular trial data confirmed initial dosing strengths for Phase 2 trial in IH v Data suggest SDX can be safely dosed at levels higher than current MPH products v Ongoing collaborative dialogue and period
Slide 6: Product Development Updates
Product Development Updates
Slide 7: Arimoclomol - Expanding Pipeline Targeting Rare Diseases
Arimoclomol - Expanding Pipeline Targeting Rare Diseases Aligns with strategy to build value through the development and commercialization of novel treatments for rare diseases Niemann-Pick disease type C High Upside Opportunity v Ultra-rare progressive, disabling Y NDA-stage investigational drug an
Slide 8: Path to Resubmission and Approval Progressing
Path to Resubmission and Approval Progressing KemPharm has significant experience with challenging regulatory situations, including two FDA product approvals that followed initial CRLs Recent Activities Regulatory Outlook * Continuing to have an ongoing collaborative + Throughoutthis process, no new
Slide 9: KP1077 — Product Candidate Overview
KP1077 — Product Candidate Overview KemPharm is advancing KP1077 as a potential therapeutic treatment for Idiopathic Serdexmethylphenidate ¥ 100% SDX with multiple dosing options v SDX has already been designated C-IV by DEA Regulatory & IP Advantages v Eligible for Fast-Track, Orphan Drug and Break
Slide 10: KP1077 — Multiple Clinical Programs Targeting Rare Sleep Indications
KP1077 — Multiple Clinical Programs Targeting Rare Sleep Indications KP1077 Represents a Potential “Portfolio in a Pill” Opportunity Idiopathic Hypersomnia Narcolepsy + Lead KP1077 indication * Second KP1077 indication would allow KemPharm + Investigational New Drug (IND) application cleared to addr
Slide 11: Financial Update and Upcoming Milestones
Financial Update and Upcoming Milestones
Slide 12: Financial Position is a Source of Strength
Financial Position is a Source of Strength Q3 2022 Income Statement Details: + Net revenue of $2.9M, primarily from the arimoclomol EAP program in France * Q3 2022 net loss attributable to common stockholders of ($6.6M), or ($0.19) per basic and diluted share, driven primarily by R&D expense of $5.4
Slide 13: KemPharm: Multiple Growth Catalysts
KemPharm: Multiple Growth Catalysts v Phase 2 trial initiation in IH by the end of 2022 v Interim Phase 2 IH data expected by mid-2023 v Phase 3 trial in narcolepsy to initiate following IH Phase 2 trial results v Potential to re-file NDA as early as Q3 2023 v Anticipated ongoing quarterly revenue f
Slide 14: KemPharm
| Ce KemPharm Addressing Rare CNS, Neurodegenerative and Lysosomal Storage Diseases For additional information please contact: Jason Rando jrando@tiberend.com